LobbyingRegeneron Pharmaceuticals lobbying by quarter
Regeneron Pharmaceuticals REGN's latest lobbying report covers Q2 2026, at $940K. The four quarters Q4 2025–Q3 2026 total $2.7M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Copyright/Patent/Trademark.
Regeneron PharmaceuticalsREGN
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $2.7M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $440K | 4 |
| Q1 2023 | $570K | 4 |
| Q2 2023 | $480K | 4 |
| Q3 2023 | $510K | 4 |
| Q4 2023 | $540K | 4 |
| Q1 2024 | $540K | 4 |
| Q2 2024 | $510K | 4 |
| Q3 2024 | $510K | 4 |
| Q4 2024 | $510K | 4 |
| Q1 2025 | $510K | 5 |
| Q2 2025 | $870K | 6 |
| Q3 2025 | $830K | 6 |
| Q4 2025 | $870K | 6 |
| Q1 2026 | $900K | 6 |
| Q2 2026 | $940K | 6 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$3.3M · 35 reports
- Copyright, patent and trademark$1.9M · 16 reports
- Medicare and Medicaid$1.9M · 16 reports
- Taxation$872K · 12 reports
- Budget and appropriations$750K · 16 reports
- Trade$692K · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES47 reports
- SENATE47 reports
- Health & Human Services, Dept of (HHS)26 reports
- Centers For Medicare and Medicaid Services (CMS)8 reports
- White House Office4 reports
- Treasury, Dept of2 reports
- Commerce, Dept of (DOC)1 reports
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseRegeneron Pharmaceuticals | $7.1M | 15 quarters |
| Crane Strategies | $750K | 15 quarters |
| Stewart Strategies and Solutions | $540K | 9 quarters |
| Checkmate Government Relations | $480K | 6 quarters |
| BGR Government Affairs | $450K | 5 quarters |
| The Washington Tax & Public Policy Group | $180K | 6 quarters |
| Arnold & Porter Kaye Scholer | $60K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BRENT ALAN DEL MONTE | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee | Q2 2026 |
| DANIEL FARMER | Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space | Q2 2026 |
| GREGORY NICKERSON | Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Subcommittee | Q2 2026 |
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| RAGHAV AGGARWAL | Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior | Q2 2026 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q2 2026 |
| STEVEN CRANE | Staff assistant, Senator Barbara Mikulski | Q2 2026 |
| TIMOTHY LUCAS BLANCHAT | Chief of Staff, Congressman Richard Hudson; Deputy State Director, Senator Thom Tillis | Q2 2026 |
| ZACHARY AUSTIN PRICE | Staff assistant to Sen. Coats | Q2 2026 |
| FREDERICK VAUGHAN | Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House | Q4 2025 |
| BOBBY MCMILLIN | General Counsel, Senate Committee on Health, Education, Labor, & Pensions (HELP) (2015-2019); Counsel, Senate HELP Committee (2015); Counsel, Sen. Chambliss (2013-2015); Regional Rep., Sen. Chambliss (2012-2013); Press Intern, Sen. Chambliss (2007) | Q4 2022 |
| SONJA NESBIT | Deputy Assistant Secretary of Legislation, U.S. Dept. of Health & Human Services (2013-2016); Deputy Staff Director, Ways and Means Committee, Subcommittee on Income Security and Family Support, U.S. House of Representatives (2002-2013) | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/03for Q2 | Crane Strategies | $50K |
| 07/20for Q2 | In-house | $630K |
| 07/20for Q2 | Arnold & Porter Kaye Scholer | $50K |
| 07/20for Q2 | BGR Government Affairs | $90K |
| 07/15for Q2 | Checkmate Government Relations | $90K |
| 07/08for Q2 | The Washington Tax & Public Policy Group | $30K |
| 05/04for Q1 | Crane Strategies | $50K |
| 04/20for Q1 | In-house | $640K |
| 04/20for Q1 | BGR Government Affairs | $90K |
| 04/20for Q1 | Arnold & Porter Kaye Scholer | Under $5,000 |
| 04/15for Q1 | Checkmate Government Relations | $90K |
| 04/01for Q1 | The Washington Tax & Public Policy Group | $30K |
| 01/21for Q4 2025 | Crane Strategies | $50K |
| 01/20for Q4 2025 | In-house | $610K |
| 01/20for Q4 2025 | BGR Government Affairs | $90K |
| 01/20for Q4 2025 | Checkmate Government Relations | $90K |
| 01/16for Q4 2025 | Arnold & Porter Kaye Scholer | Under $5,000 |
| 01/16for Q4 2025 | The Washington Tax & Public Policy Group | $30K |
| 25/10/20for Q3 2025 | In-house | $570K |
| 25/10/20for Q3 2025 | BGR Government Affairs | $90K |